I wonder whyCZO would rerelease a news item originally released in March? The new edition is a bit more flowery with some quotes from the researchers along the lines of if something happens in the future there is a chance this could be a very good thing. A throw away line that can never come back to bite because it is pure supposition. Why would Gilles float this out now so close to the AGM and right before 1Q numbers drop. I wonder,,hmmm.
I am also concerned that the study has turned from YBG being a carrier to being a stand alone treatment. To my mind the safe and sure way forward is to first use it as a carrier for drugs already authorised, and then as a stand alone. This is what happened to the OBG trial. Everyone got excited about OBG as a stand alone treatment and forgot about using it as an adjunct to Statins. We remember how that went.
Gilles has never gotten a single PGX derived formulation into the market in 15 years we dont need a home run right now but we really need to get a hit to prove it can be done.
What ever happened to the short list of life scince companies for CoQ10?
THat is the deal that needs to happen right now, that is money this year, that is validation of the PGX. Dont be distracted by another slight of hand trick another could be, maybe, might be, promising lab results, just a few more years....... or I gaurantee we will all be back here next year doing this yet again.